SYNDIVIA
Pre-clinicalSyndivia advances cancer treatment with its GeminiMab ADC platform, enabling site-specific hinge-conjugated antibody-drug conjugates (ADCs) and other antibody conjugates with optimized drug-to-antibody ratios (DAR1, DAR2, DAR4) in single- or combo-payload formats.
Founded
2017
Focus
Biologics
About
Syndivia advances cancer treatment with its GeminiMab ADC platform, enabling site-specific hinge-conjugated antibody-drug conjugates (ADCs) and other antibody conjugates with optimized drug-to-antibody ratios (DAR1, DAR2, DAR4) in single- or combo-payload formats.
Company Info
TypePrivate
Founded2017
LocationParis, France
StagePre-clinical
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile